Tag: Mind Cure - Psilocybin Alpha

New Resource: Psychedelics Drug Development Tracker

Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors

Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors

Post published:February 22, 2021
Post category:Press Release

MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform

MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform

Post published:February 18, 2021
Post category:Press Release

Mind Cure Comments on Recent Promotional Activity

Mind Cure Comments on Recent Promotional Activity

Post published:February 17, 2021
Post category:Press Release

MINDCURE’s Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization

MINDCURE’s Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization

Post published:February 16, 2021
Post category:Press Release

MINDCURE Announces Listing of Warrants

MINDCURE Announces Listing of Warrants

Post published:February 11, 2021
Post category:Press Release

Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option

Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option

Post published:February 10, 2021
Post category:Press Release

MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category

MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category

Post published:January 26, 2021
Post category:Press Release

Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering

Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering

Post published:January 22, 2021
Post category:Press Release

Mind Cure Health Inc. Announces $10 Million Bought Deal Public Offering

Mind Cure Health Inc. Announces $10 Million Bought Deal Public Offering

Post published:January 21, 2021
Post category:Press Release

Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy

Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy

Post published:January 12, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.